MedTrace Logo

The Human Mucosal Immune Responses to Influenza Virus (SLVP026)

NCT03023553 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2017-04-21

Study results available
· View outcomes & findings →

Summary

This study will examine the immune responses to the seasonal influenza vaccine in single cells of the nasal passages when compared with cells in circulating blood.

Conditions

Interventions

BIOLOGICAL

Fluzone®

Influenza Virus Vaccine Suspension for Intramuscular Injection

BIOLOGICAL

FluMist®

Influenza Virus Vaccine Live, Intranasal Spray

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia Dekker, MD · Stanford University

  • Harry Greenberg, MD · Stanford University

  • Xiaosong He, PhD · Stanford Universityh

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-02-28
Completion
2013-02-28

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03023553 on ClinicalTrials.gov